oai:pubmedcentral.nih.gov:1066...
BioMed Central
BMC Neuroscience
2023
12/11/2023
Polycystic ovarian syndrome (PCOS) is a known endocrine disorder that has affected many women of childbearing age, and is accompanied by various neurodegenerative conditions.
Hence, this study investigates the impact of butyrate in reversing hypothalamic-related disorder, possibly through γ aminobutyric acid (GABA) in a rat model of PCOS.
Eight-week-old female Wistar rats were allotted into four groups (n = 5), which include control, butyrate, letrozole, and letrozole + butyrate groups.
PCOS was induced by administering 1 mg/kg of letrozole (oral gavage) for 21 days.
After confirmation of PCOS, 200 mg/kg of butyrate (oral gavage) was administered for 6 weeks.
Rats with PCOS were characterized by elevated levels of plasma insulin and testosterone.
Increases in plasma and hypothalamic triglyceride levels, inflammatory biomarker (SDF-1), apoptotic marker (caspase-6), and decreased plasma GnRH were observed.
Additionally, a decrease in hypothalamic GABA was revealed.
Nevertheless, the administration of butyrate attenuated these alterations.
The present study suggests that butyrate ameliorates hypothalamic inflammation in an experimental model of PCOS, a beneficial effect that is accompanied by enhanced GABA production.
Eepho, Oony-Iye,Bashir, Al-Amin M.,Oniyide, Adesola A.,Aturamu, Ayodeji,Owolabi, Olutunmise V.,Ajadi, Isaac O.,Fafure, Adedamola A.,Ajadi, Mary B.,Areloegbe, Stephanie E.,Olaniyi, Kehinde S., 2023, Modulation of GABA by sodium butyrate ameliorates hypothalamic inflammation in experimental model of PCOS, BioMed Central